Efficacy and safety of Herbal Drink in moderate COVID-19 patients: pilot study

Giving Mind Nirvana Soul Foundation0 个研究点目标入组 100 人开始时间: 2022年1月25日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. 20 to 60 years of age 2. Diagnosis of COVID-19 infection confirmed by RT-PCR test for SAR-CoV-2 3. moderate COVID-19 symptoms 4. No uncontrollable underlying disease 5. Onset of symptoms is within 5 days or positive RT-PCR for SAR-CoV-2 within 5 days 6. Signed informed consent provided by patient 7. Willing to stay at research site at least 10 days

•1. COVID19 positive based on Antigen test but PCR negative 2. Severe or critical clinical conditions (Glasgow coma scale less than 14) 3. Severe COVID-19 4. Patient who is on mechanical ventilator 5. Abnormal chest x-ray 6. Dyspnea or respiratory rate above 30 per minute 7. Hypoxia or oxygen saturation less than 96 percent 8. Underlying diseases including Diabetes mellitus, uncontrollable hypertension 9. Abnormal liver function test: ALT/AST increased 5 times higher than the upper limit of normal or with Child Pugh C 10. Renal failure or Creatinine clearance (Cockcroft-Gault Equation) less than 30 ml/min or having hemodialysis/peritoneal dialysis 11. Known allergy or hypersensitivity to Herbal Drink 12. Pregnant (female of childbearing age with positive urine pregnancy test) or Lactating female

发起方

Giving Mind Nirvana Soul Foundation